30 Million People experience an unexpectedly positive Side Effect of Fat Loss Peptides

7:27

30 Million People experience an unexpectedly positive Side Effect of Fat Loss Peptides

Physionic 04.06.2026 18 220 просмотров 1 084 лайков

Machine-readable: Markdown · JSON API · Site index

Смотреть на YouTube

Поделиться Telegram VK Бот

Транскрипт Скачать .md

Анализ с AI

Описание видео

*JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT]* Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2 *HEALTH AUTONOMY [COURSE]* Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy *JOIN THE COMMUNITY* Join my Community [It’s Free!]: https://bit.ly/PhysionicCommunity2 *EMAIL LIST* 1-2 Weekly Email of Value [It’s Free!]: http://bit.ly/2AXIzK6 *HIRE ME FOR CONSULTING:* Consulting: https://bit.ly/3dmUl2H Created with Biorender 0:00 - Introduction 0:30 - A Peptide for my Liver, Please 1:49 - I’ll Keep my Weight, though 3:49 - An Unlikely Alliance Other videos on Peptides: Osteoarthritis: https://www.youtube.com/watch?v=72rzR4Qo3zo The Most Potent Peptide: https://www.youtube.com/watch?v=T9KJ8HGRmwM Visceral Fat Specific: https://www.youtube.com/watch?v=m5BcB5_dWic References [Study 799] Gonzalez-Rellan MJ, Riobello C, Fang S, et al. The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors. Cell Metab. Published online 2026. doi:10.1016/j.cmet.2026.03.011 Funding/Conflicts: Public Funding: From the study, the work was funded by grants from the Canadian Institutes of Health Research; Non-Profit Funding: From the study, funding also came from a Sinai Health–Novo Nordisk Foundation Fund in Regulatory Peptides; Industry Funding: From the study, no direct industry funding source was reported, but D.J.D. disclosed consulting fees from Amgen, AstraZeneca, Crinetics, Eli Lilly, and other companies, and Mount Sinai Hospital has received investigator-initiated grant support from industry sponsors for preclinical studies in the Drucker lab. [Study 800] Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. doi:10.1056/NEJMoa2028395 Funding/Conflicts: Public Funding: From the study, no public funding source was reported; Non-Profit Funding: From the study, no non-profit funding source was reported; Industry Funding: From the study, the trial was funded by Novo Nordisk, and conflicts included multiple authors being employees of Novo Nordisk, holding Novo Nordisk stock, or receiving advisory, consulting, lecture, travel, research, or grant support from Novo Nordisk and other pharmaceutical companies; the authors stated no other potential conflict of interest relevant to the article was reported. [Study 801] Sanyal AJ, Newsome PN, Kliers I, Harms Østergaard L, Long MT, Kjær MS, et al. Phase 3 trial of semaglutide in metabolic dysfunction–associated steatohepatitis. N Engl J Med. 2025;392(21):2089-2099. doi:10.1056/NEJMoa2413258 Funding/Conflicts: Public Funding: From the study, no public funding source was reported; Non-Profit Funding: From the study, no non-profit funding source was reported; Industry Funding: From the study, the trial was funded/supported by Novo Nordisk, and the paper stated that author disclosure forms were available with the full article; several listed author affiliations were with Novo Nordisk. [Study 802] Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjær MS, Krarup N, et al. Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511-522. doi:10.1016/S2468-1253(23)00068-7 Funding/Conflicts: Public Funding: From the study, no public funding source was reported; Non-Profit Funding: From the study, no non-profit funding source was reported; Industry Funding: From the study, the trial was funded by Novo Nordisk A/S, and conflicts included author relationships with Novo Nordisk and other pharmaceutical companies, with the paper noting disclosure forms were provided by the authors. Please use the following link to submit your critique: https://bit.ly/PhysionicCritique Disclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.

Оглавление (4 сегментов)

Introduction

We've covered peptides multiple times now from the supreme fat loss and metabolism peptides to the visceral fat specific peptides and even the impact on osteoarthritis. But now I'd like to turn our attention to the liver because something unexpected happens to our liver when we use peptides according to new research. It's probably no shock to you that uh when you apply peptides like semiglutide and then measure liver health, there's improvements. We see

A Peptide for my Liver, Please

that here by measures of two specific enzymes called ALT and ASD. Now, in fact, when you get your blood work, they're the major enzymes that your physician looks at as a first pass look at your liver health. When your liver is stressed, and I don't mean it like a chain smoking and drinking Jack Daniels kind of stress. I'm saying that the cells are damaged and dying. They release these proteins, these enzymes. So, the higher the bars, the worse. I'm going to have you focus on only the first two bars for now because the second two begin unraveling how these peptides have unique effects. The bar on the left is the data for mice not exposed to the peptide and the right blue one is the peptide exposure. Clearly, there's improvements and this applies to human research too as we see here shows huge improvements in liver health through similar measures. The lower the lines go, the less of these proteins are secreted and therefore less liver harm is occurring. Okay, like I said, that may or may not be news to you. And if it's not, well, don't worry. That's not why you're here. So far, plainly spoken, we can say that fat loss peptides like semiglutide reduce liver harm markers. Now, let's return to these

I’ll Keep my Weight, though

data and introduce the right side. It's the exact same conditions except that both groups have the GLP-1 receptor knocked out in the brain cells called neurons. So typically the semiglutide peptide mimics GLP-1 hormone and travels to the brain binding it and causing weight and fat loss through severely dampened hunger. However, now those receptors that it binds to are gone and yet we see that both liver markers are still improved. I can also tell you that there was predictably no weight or fat loss. That is critically important. This means that we are still seeing liver improvements independent of weight loss and fat loss. How cool is that? Now, this of course raises a huge question. How are these peptides having an effect if one of their primary mechanisms of action is knocked out? Well, for one, there were direct changes to the immune profile surrounding the liver. This matters because our immune system is intimately tied to liver harm if it's overactive as immune cells invade into the liver and release pro-inflammatory damaging molecules as a reaction to liver cells promoting a pro-inflammatory state. But this actually just opens a gateway to an unlikely relationship between peptides and your liver. It has to do with certain immune cells and something that they share with another important group of cells in your liver. Before I get into that, I should mention that not all liver indices improve in a weight loss independent manner. It depends on the severity and the length of time of your liver has been suffering from excessive stress. Some improvements may be fat loss dependent. So when we remove this mechanism, it does impact the overall effect of peptides. Though returning to these fat loss

An Unlikely Alliance

weight loss independent effects, when we screen the liver for cells, there's 17 distinct cell types that come out and the GLP-1 receptor expression or presence on these cells is especially high in two cell types. One is an immune cell called a T- cell and the other is an endothelial cell which is part of your cardiovascular system. And naturally, if we're discussing weight loss independent effects, these could be prime targets that are tightly related to the liver for GLP-1 like peptides to bind to and enact an effect. Right? So, one way that we can probe how important these are in liver health is to eliminate their GLP-1 receptors and see if there's a measurable influence. Sure enough, check this out. Same measures, liver ALT and A markers of damage and stress, the animals without the GLP-1 receptors knocked out, so the receptors are present, experience improvements shown in the gray bars. But the ones with the GLP-1 receptors knocked out in the light green at the end there did not experience the same improvements. Remember, lower is better. I know the light green bar there looks notably lower than the darker green comparator, but statistically there were no improvements. This means that these two cell types, the T- cells and the endothelial cells are having some sort of positive impact on liver health through these peptides. This is where the research takes one step further, but I'm taking things several steps further because if you're interested to learn how these cells positively impact the liver, independent of weight loss, or other peptide specific benefits on the liver, or even future clinical measures that indicate liver health improvements that may be independent of fat loss, then check out my full analysis. It's a longer video packed with more detail and it comes with a fulllength article and much more shown right here. If you're interested, just join my research platform. It's called the Physionic Insiders. The link to check it out is in the description box. Ultimately, when separating out the specific impact of endothelial cells, which in a bit more detail, these cells that line your blood vessels and control your blood vessels, there's an assumed unique effect that works through these endothelial cells. Somehow, the peptides binding these endothelial cells within the liver vascule leads to positive changes on liver health. Admittedly, while the research isolates these endothelial cells from the TE-C cells with high GLP-1 receptor density and shows that liver there are liver improvements, there was never a reciprocal experiment for the TE-C cells. So, we don't know if the positive liver effects are specific to the liver endothelial cells or if there's unique effects by the TE-C cells as well. This is definitely novel research and there are human studies that indicate some form of liver improvement from GLP1 receptor agonist peptide use like semiglutide. But none of these studies are able to tease out the fat loss independent effects of semiglutide which is why this study and the mechanistic insight is especially exciting. Now I'd certainly like to see more like the cross talk between the endothelial cells and the rest of the liver but it's an exciting first step. The peptides just keep peptiding. I cover much more on their incredible effects right here if you're inclined to learn more. Thanks for nerding out with me. I'll catch you in the next one. See you.

Другие видео автора — Physionic

Ctrl+V

Экстракт Знаний в Telegram

Экстракты и дистилляты из лучших YouTube-каналов — сразу после публикации.

Подписаться

Лучшие методички за неделю — каждый понедельник